STRASBOURG, France--(BUSINESS WIRE)--
Regulatory News
Transgene (Paris:TNG) today announced its financial reporting dates for 2021:
March 10, 2021: |
2020 Fiscal Year Results |
|
|
April 27, 2021: |
First Quarter 2021 Financial Results |
|
|
May 26, 2021: |
Annual Shareholders' Meeting |
|
|
September 22, 2021: |
First Half 2021 Financial Results |
|
|
November 4, 2021: |
Third Quarter 2021 Financial Results |
About Transgene
Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.
The Company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac® platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO™ platform).
With Transgene’s myvac® platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac® approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO™ collaboration with AstraZeneca.
Additional information about Transgene is available at:
Follow us on Twitter:
View source version on businesswire.com:
